| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM199407283310406 |
| P698 | PubMed publication ID | 8015571 |
| P50 | author | Milton Weinstein | Q30223679 |
| P2093 | author name string | Neumann PJ | |
| Gharib SD | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 239-243 | |
| P577 | publication date | 1994-07-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | The cost of a successful delivery with in vitro fertilization | |
| P478 | volume | 331 |
| Q54058664 | 'Cheaper than a newcomer': on the social production of IVF policy in Israel. |
| Q71828146 | A cost and outcome model of fertility treatment in a managed care environment |
| Q49167482 | A health-economic decision-analytic model comparing double with single embryo transfer in IVF/ICSI. |
| Q33843867 | A historical perspective of the clinical evolution of the assisted reproductive technologies |
| Q42680644 | An estimate of the cost of in vitro fertilization services in the United States in 1995 |
| Q34393122 | Association between Beckwith-Wiedemann syndrome and assisted reproductive technology: a case series of 19 patients. |
| Q33955901 | Bioethics for clinicians: 26. Assisted reproductive technologies |
| Q93023386 | Business models and provider satisfaction in in vitro fertilization centers in the USA |
| Q36455626 | Cost and efficacy comparison of in vitro fertilization and tubal anastomosis for women after tubal ligation |
| Q53638760 | Cost effectiveness of in vitro fertilization. |
| Q77664342 | Cost-effective treatment of the infertile couple |
| Q48891407 | Cost-effectiveness of IVF in women 38 years and older |
| Q37874674 | Cost-effectiveness of hysterosalpingography, laparoscopy, and Chlamydia antibody testing in subfertile couples |
| Q54443294 | Cost-effectiveness of in vitro fertilization and embryo transfer. |
| Q30369601 | Distributive justice and infertility treatment in Canada. |
| Q37070238 | Donor insemination and infertility: what general urologists need to know |
| Q33948345 | Economics of prematurity in the era of managed care. |
| Q35040343 | Economics of treatments for male infertility |
| Q64990037 | Evaluating the Utility of Intralipid Infusion to Improve Live Birth Rates in Patients with Recurrent Pregnancy Loss or Recurrent Implantation Failure. |
| Q50673122 | Expression of sHLA-G in supernatants of individually cultured 46-h embryos: a potentially valuable indicator of 'embryo competency' and IVF outcome. |
| Q48972177 | Factors that affect outcome of in-vitro fertilisation treatment |
| Q35068945 | Failures in assisted reproductive technology: an overview |
| Q34412653 | Fertility options after vasectomy: a cost-effectiveness analysis |
| Q47160564 | Fertility preservation of patients with testicular cancer |
| Q34353325 | Funding in vitro fertilization treatment for persistent subfertility: the pain and the politics |
| Q33947556 | Genetic technologies and achieving health for populations |
| Q57732269 | IVF cycle cost estimation using Activity Based Costing and Monte Carlo simulation |
| Q40432755 | In vitro fertilization versus tubal surgery: is pelvic reconstructive surgery obsolete? |
| Q40953136 | In vitro fertilization: a cost-effective alternative for infertile couples? |
| Q72355951 | In-vitro fertilisation and health care coverage |
| Q41658858 | Infertility and in vitro fertilization. A growing need for consumer-oriented regulation of the in vitro fertilization industry |
| Q33835652 | Infertility: from a personal to a public health problem. |
| Q71975750 | Infertility: we're not taking new patients! |
| Q43550851 | Insurance coverage and in vitro fertilization outcomes: a U.S. perspective |
| Q73742757 | Intensive hormone monitoring in women with unexplained infertility: evidence for subtle abnormalities suggestive of diminished ovarian reserve |
| Q41318902 | Is assisted reproduction the optimal treatment for varicocele-associated male infertility? A cost-effectiveness analysis |
| Q51531583 | Is propofol a proper proposition for reproductive procedures? |
| Q33936566 | Is screening for Chlamydia trachomatis infection cost effective? |
| Q40982935 | Is there ever a role for tubal surgery? |
| Q46361879 | Maternal and neonatal morbidity associated with in vitro fertilization |
| Q71729981 | Now that we have painted ourselves in a corner |
| Q40084630 | One danger of biomedical enhancements |
| Q42442025 | Preprogrammed, unmonitored ovarian stimulation reduces expense without compromising the outcome of assisted reproduction |
| Q46491827 | Pricing in vitro fertilization procedures |
| Q52222697 | Prospective randomized trial comparing the outcome and cost of in vitro fertilization with that of a traditional treatment algorithm as first-line therapy for couples with infertility. |
| Q37431745 | Public financing of IVF: a review of policy rationales. |
| Q37142423 | Reassessing reconstruction in the management of obstructive azoospermia: reconstruction or sperm acquisition? |
| Q71215408 | Recanalization of obstructed fallopian tube by selective salpingography and transvaginal bougie dilatation: outcome and cost analysis |
| Q36270930 | Reflections on the cost-effectiveness of recombinant FSH in assisted reproduction. The clinician's perspective |
| Q58174879 | Should government fund assisted reproductive techniques? A study using willingness to pay |
| Q33913224 | Socioeconomic disparities in the use and success of fertility treatments: analysis of data from a prospective cohort in the United States. |
| Q40463798 | Subfertility in the era of assisted reproduction: changes and consequences |
| Q49060065 | Successful pregnancy in a bone marrow transplant recipient following oocyte donation |
| Q33346965 | The ESEP study: salpingostomy versus salpingectomy for tubal ectopic pregnancy; the impact on future fertility: a randomised controlled trial |
| Q28386648 | The attributable annual health costs of U.S. occupational lead poisoning |
| Q36515611 | The combined effect of age and basal follicle-stimulating hormone on the cost of a live birth at assisted reproductive technology |
| Q50141819 | The cost of infertility evaluation and therapy: findings of a self-insured university healthcare plan |
| Q50162590 | The economic cost of infertility-related services: an examination of the Massachusetts infertility insurance mandate |
| Q40463801 | The efficacy and cost effectiveness of embryo cryopreservation compared with other assisted reproductive techniques |
| Q39674342 | The efficiency of a group-specific mandated benefit revisited: the effect of infertility mandates |
| Q48949927 | The geriatric gravida: multifetal pregnancy reduction, donor eggs, and aggressive infertility treatments |
| Q77089958 | The medical marketplace and the diffusion of technologies |
| Q71857589 | The perinatal paradox |
| Q50789308 | Urology Update from Jackson Hole: Highlights from the 3rd Annual Jackson Hole Summer Urologic Conference July 28-August 3, 2001, Jackson Hole, WY. |
| Q37887459 | Use of algorithmic pathways to develop quality, cost-effective clinical care |
| Q36630981 | Use of multivitamins, intake of B vitamins, and risk of ovulatory infertility |
| Q40821730 | Using conjoint analysis to take account of patient preferences and go beyond health outcomes: an application to in vitro fertilisation |
| Q37968228 | Utilization of infertility treatments: the effects of insurance mandates |
| Q43275634 | Why the NHS should fund infertility services |
Search more.